Ultomiris Demonstrated 43.4% Reduction in Proteinuria vs Placebo in Adults With Immunoglobulin A Nephropathy at 34 Weeks in I CAN Phase III Trial
June 09, 2026
June 09, 2026
WILMINGTON, Delaware, June 9 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
ULTOMIRIS(R) (ravulizumab-cwvz) demonstrated 43.4% reduction in proteinuria vs placebo in adults with immunoglobulin A nephropathy at 34 weeks in I CAN Phase III trial
Rapid reduction in proteinuria observed as early as week 10 and sustained through week 34, supporting potential of ULTOMIRIS as a disease-modifying treatment
Results . . .
* * *
ULTOMIRIS(R) (ravulizumab-cwvz) demonstrated 43.4% reduction in proteinuria vs placebo in adults with immunoglobulin A nephropathy at 34 weeks in I CAN Phase III trial
Rapid reduction in proteinuria observed as early as week 10 and sustained through week 34, supporting potential of ULTOMIRIS as a disease-modifying treatment
Results . . .